|
4SC AG, founded in 1997 and based in Martinsried, Germany, is a drug discovery and development company. The firm's cheminformatics-based technology platform allows it to provide biopharmaceutical companies with a wide range of drug discovery services. The virtual high-throughput screening (HST) 4SCan (R) technology supports biological, medicinal chemistry, and parallel synthetic chemistry research processes. Referencing protein structure, homology model, and compound biological activity information, the system predicts molecule efficacy. 4SC focuses on inflammation, cancer, and infectious disease research. It has built a library of 4.6 million small molecule drug candidates. Additional combinatorial databases contain over 10 million chemical scaffolds. 4SC has found over $30 million in financing from 3i, Bayern Kapital, Beteiligungsgesellschaft der Deutschen Wirtschaft mbH, BioM AG, DVC, Mulligan BioCapital AG, and tbg.
|